mRNA cell therapies
搜索文档
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Globenewswire· 2025-04-01 19:00
公司活动 - 公司管理层预计于2025年4月8日周二下午2点15分(美国东部时间)参加第24届Needham虚拟医疗保健会议的炉边谈话 [1] - 演讲和炉边谈话的直播预计可在公司网站www.cartesiantherapeutics.com的活动板块观看,活动存档回放也将在有限时间内提供 [2] 公司业务 - 公司是一家临床阶段的生物技术公司,致力于开发用于治疗自身免疫性疾病的mRNA细胞疗法 [3] - 公司的主要资产Descartes - 08是一种mRNA CAR - T,正在进行针对全身性重症肌无力患者的3期临床试验和针对系统性红斑狼疮的2期临床试验,并计划在其他自身免疫性适应症中开展2期篮子试验,其针对全身性重症肌无力患者的3期试验已在特殊协议评估流程下获得FDA的书面同意 [3] - 公司临床阶段的产品线还包括Descartes - 15,这是一种下一代自体抗BCMA mRNA CAR - T,目前正在多发性骨髓瘤患者中进行1期试验 [3] 联系方式 - 投资者联系人为Megan LeDuc,邮箱为megan.leduc@cartesiantx.com [4] - 媒体联系人为David Rosen,邮箱为david.rosen@argotpartners.com [4]
Cartesian Therapeutics(RNAC) - Prospectus(update)
2024-09-21 04:17
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 20, 2024 Registration No. 333-281204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER Carsten Brunn, Ph.D. President and Chief Executive Officer Cartesian Therapeutics, Inc. 704 Quince Orchard Road Gaithersburg, MD 20878 (617) 923-1400 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: ...
Cartesian Therapeutics(RNAC) - Prospectus(update)
2024-09-10 04:11
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 9, 2024 Registration No. 333-281204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cartesian Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 26-1622110 (I.R.S. ...
Cartesian Therapeutics(RNAC) - Prospectus
2024-08-02 19:34
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 2, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cartesian Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 2834 26-1622110 (I.R.S. Employer Identification No.) 704 Quince Orchard Road Ga ...